Cargando…
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors
Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engin...
Autores principales: | Tsai, Alexander K., Davila, Eduardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910704/ https://www.ncbi.nlm.nih.gov/pubmed/27467930 http://dx.doi.org/10.1080/2162402X.2015.1122158 |
Ejemplares similares
-
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020) -
Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies
por: Xiu, Huiqing, et al.
Publicado: (2022) -
Engineering the next generation of cell-based therapeutics
por: Bashor, Caleb J., et al.
Publicado: (2022) -
Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
por: Balvers, Rutger K., et al.
Publicado: (2014) -
A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: Toward applications for Crohn's disease
por: McKay, Ryan, et al.
Publicado: (2018)